340B News

HRSA Approves Plans From 10 Drugmakers for 2027 340B Rebate Pilot

Published · Updated

New manufacturer notices clarify Beacon setup, claims reporting and the work ahead of the January 1, 2027 start.

We published a companion article listing selected related medications for drugs included in the rebate model and whether those products are also listed: 2027 340B Rebate Pilot Drugs and Selected Related Products. This reference does not recommend medication changes.

Prescription bottles behind a pharmacy counter, with Rebate labels only on the blue-capped bottles.

HRSA has posted approved 340B rebate plans from ten drug manufacturers, with every manufacturer on the current list scheduled to begin January 1, 2027. All ten will use the Beacon Rebate Model Platform. For covered entities purchasing the affected drugs, that means preparing to pay wholesale acquisition cost (WAC) and collect the 340B discount afterward. [1]

October 3 update: manufacturer notices are out

The manufacturer communications distributed through Beacon turn the January 1, 2027 start into specific setup and reporting tasks. This update reviews notices from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Merck and Teva. The ten-manufacturer HRSA approval list below remains the program-wide reference.

  • Check registration and banking now. An existing 340B ESP account does not enroll your entity in Beacon, and earlier Beacon registrations may require refreshed documentation and bank verification. [5] [13]
  • Map each product to its required reporting systems. Some notices move pilot claims out of ESP; AstraZeneca expressly retains Farxiga ESP reporting, and Amgen retains its separate claims-data requirements. [11] [9]
  • Give pharmacy, your TPA and finance the same instructions. Enrollment, claims submission and receipt of an ACH payment are separate steps. The comparison below identifies the differences to build into your workflow.

Compare the manufacturer notices or open Beacon's current policy documents and submission templates.

The practical question is how that payment will make its way back to your organization. Someone will need to submit the claim, resolve missing information, match the rebate to the right transaction, and follow up when the money does not arrive. Pharmacy may see the change first, but finance, billing, and the people managing your data need a place in the conversation now.

Which manufacturers and drugs are included?

HRSA's approval table lists the following manufacturers and products. Each row has a January 1, 2027 start date and identifies Beacon as the platform. The product links below open the plans posted by HRSA. [1]

Approved manufacturers and listed products
ManufacturerProducts listed by HRSA
AbbVieImbruvica, Linzess, Vraylar
AmgenEnbrel, Otezla, Otezla XR
AstellasXtandi
AstraZenecaFarxiga
Bristol Myers SquibbEliquis, Pomalyst
Boehringer IngelheimJardiance, Ofev, Tradjenta
GSKBreo Ellipta, Trelegy Ellipta
MerckJanuvia, Janumet, Janumet XR
PfizerIbrance
TevaAustedo, Austedo XR

Use this list to start your review, then match the approved 11-digit National Drug Codes (NDC-11s) against your purchasing and dispensing records. A brand name alone is not enough to configure a purchasing system. The pilot is limited to approved selected drugs for Medicare's 2026 and 2027 initial price applicability years, during their applicable pricing periods. Within that scope, it applies regardless of payer or indication. Drugs without an approved rebate plan continue under upfront 340B pricing. [1] [2]

The 340B account stays. The payment timing changes.

HRSA directs covered entities to keep purchasing pilot drugs through their existing 340B wholesaler accounts, with WAC loaded for the affected products when the plan takes effect. Buying through a separate WAC-only or group purchasing organization (GPO) account is not the ordering route HRSA describes for a pilot rebate. The rebate equals WAC minus the 340B ceiling price on the date of dispense and is paid at the unit level. [1]

That distinction deserves a conversation with the wholesaler before January. An account can still be labeled “340B” while the amount due on an affected purchase increases. Finance will need to understand that change, the expected rebate receivable, and how a payment will be reconciled.

The pilot is voluntary for manufacturers. Covered entities should not assume that means they can choose to retain upfront discounts for an approved product. AbbVie's October 2 notice, for example, says the selected Imbruvica, Linzess and Vraylar NDCs will receive the 340B price exclusively through rebates. Entity-specific exceptions require a separate review: GSK's plan allows AIDS Drug Assistance Program (ADAP) covered entities already receiving 340B discounts through rebates to continue their existing rebate processes. [5] [6]

Two clocks will matter to your team

Claims submission: HRSA describes a 45-calendar-day window from the date of dispense, with allowances for extenuating circumstances and changes in a claim's 340B status. The manufacturer plans explain how to request those allowances. Payment: the federal notice requires payment or a documented denial within ten calendar days of a completed submission. When a submission is returned as incomplete, the payment clock restarts after the necessary data is submitted. [2]

The ten-day standard does not mean the cash-flow gap begins and ends ten days after a drug is purchased. Inventory timing, the dispense date, submission timing, and corrections all affect when money returns. Our recommendation is to model that full cycle using your own purchasing volume and payment terms.

The new notices preserve a payment-calendar detail worth resolving. AbbVie and Teva describe payment within ten calendar days excluding federal holidays, while HRSA's notice states ten calendar days without that qualifier. Obtain written clarification before configuring your expected-payment dates. This article does not treat the manufacturer qualifier as a change to HRSA's standard. [2] [5] [13]

Beacon registration is only the first step

Manufacturers must cover the cost of the submission platform. Your team will still need a workable process for extracting data, correcting claims, and reconciling payments. HRSA limits the submission fields and says purchasing data and encounter-level data are not permitted as part of the pilot at this time. It also provides separate pharmacy and medical claims field lists. [1] [2]

Use the Beacon Rebate Model platform. Register at cm.beaconchannelmanagement.com. AbbVie and Teva explicitly say an ESP account does not substitute for Beacon registration. Boehringer also distinguishes the Beacon Rebate Model platform from the separate Beacon MFP platform. [5] [13] [12]

New registrations require organizational verification and ACH setup. The notices identify documents such as Articles of Incorporation, IRS letter CP 575 and a bank letter, followed by micro-deposit verification. AbbVie, Amgen, Astellas, BMS and Merck say previously registered entities must reconfirm documentation and complete updated bank verification. Assign an authorized administrator and finance contact to complete those steps. [5] [9] [10] [8] [7]

Astellas recommends completing registration by December 26, 2026 and says documentation review may take up to five business days. It expressly states there is no registration deadline; December 26 is its recommendation, not a program-wide cutoff. Our recommendation is to complete setup earlier so holiday schedules do not compress the available time. [10]

If a TPA will submit claims, confirm that its Beacon integration is ready and that your entity has authorized it. BMS and Amgen expressly describe this approval step. Download the current pharmacy and medical claims templates and test NDC-11s, units, required fields and reconciliation identifiers before the first submission. [8] [9]

Beacon does not replace every existing reporting requirement

The same platform supports different manufacturer instructions. Use the applicable notice to configure each product's claims destination, pharmacy eligibility and continuing data requirements. The comparison covers the nine notices reviewed for this update; Pfizer remains on HRSA's approved list above.

What the manufacturer notices say for the January 1, 2027 transition
Manufacturer and pilot productsReporting and setup instructions
AbbVie
Imbruvica, Linzess, Vraylar
Submit the selected-drug claims to Beacon. Contract-pharmacy claims for those drugs will no longer be accepted in ESP; other AbbVie contract-pharmacy claims continue in ESP under its separate policy. Its contract-pharmacy eligibility requirements remain in place. [5]
Amgen
Enbrel, Otezla, Otezla XR
Use Beacon for pilot rebates. Inclusion in the pilot does not exempt these products from the separate pharmacy and medical claims-data collection requirements under Amgen's 340B Integrity Policy. [9]
Astellas
Xtandi
Submit required Xtandi claim data to Beacon. Astellas says its Contract Pharmacy Policy still applies. Its notice also calls for renewed bank verification for previously registered Beacon accounts. [10]
AstraZeneca
Farxiga
Submit rebate claims to Beacon and continue Farxiga claims reporting to 340B ESP. The October 2 notice retains AstraZeneca's Contract Pharmacy and In-House Claims Policies. [11]
Boehringer Ingelheim
Jardiance, Ofev, Tradjenta
Move pilot-product claims from ESP to Beacon for purchases on or after January 1, 2027. ESP remains in use for non-pilot claims and contract-pharmacy designations. The contract-pharmacy policy still applies to pilot products. [12]
Bristol Myers Squibb
Eliquis, Pomalyst
Submit eligible-product claims to Beacon in accordance with BMS's Contract Pharmacy Practice. Authorize your TPA in Beacon if it will submit on your behalf; do not assume an existing TPA relationship completes that step. [8]
GSK
Breo Ellipta, Trelegy Ellipta
Move contract-pharmacy and in-house claims for these products to Beacon; ESP will no longer accept them. Other GSK products remain in ESP under its separate policy. ADAP entities already receiving 340B discounts through rebates may keep their existing rebate process. [6]
Merck
Januvia, Janumet, Janumet XR
Move contract-pharmacy and in-house claims for these products to Beacon; ESP will no longer accept them. Other applicable Merck products continue in ESP. Merck's Program Integrity Initiative remains applicable. [7]
Teva
Austedo, Austedo XR
Register separately for Beacon even if your entity uses ESP or another Second Sight platform. Teva's existing contract-pharmacy policy continues to apply to rebate-model purchases. [13]

Keep a routing list by NDC-11 and effective date, including any separate claims-data feed and pharmacy designation. Have the TPA show which records it sends to each system before changing the current process.

Build a way to resolve unpaid claims

HRSA prohibits denying pilot rebates based on concerns about covered-entity eligibility, diversion, or Medicaid duplicate discounts, or a perceived lack of WAC purchases. Those concerns must go through HRSA or the applicable statutory review processes. Other denials require supporting reasons and documentation. These limits do not remove a covered entity's underlying compliance obligations. [2]

That protection does not mean every submitted claim will be paid. Missing data, duplicate rebate requests, and coordination with Medicare's maximum fair price (MFP) require attention. BMS describes circumstances in which an MFP refund below the 340B ceiling price can make a claim ineligible for a 340B rebate. AbbVie also describes possible 340B denials when MFP is lower. Teva says it will pay an approved 340B rebate and adjust the overlapping MFP refund through the Medicare Transaction Facilitator. Keep the manufacturer's actual denial reason and supporting information with the claim record; one manufacturer's MFP handling should not be assumed for another. [8] [5] [13]

For registration, submission and payment questions, contact Beacon at support@beaconchannelmanagement.com or 1-878-788-8907. The linked notices identify manufacturer contacts for escalation. [7] [13]

HRSA tells covered entities to work first with the manufacturer and platform vendor, then raise unresolved issues with 340BPricing@hrsa.gov after good-faith efforts. Its page still labels the planned rebate-unavailable form link as forthcoming. An internal log of submission dates, responses, payment amounts, and follow-up will make that escalation more useful. [1]

A revised pilot with a familiar concern

The earlier pilot, intended to start in January 2026, was halted by litigation. HRSA says the original notices and approvals were vacated on February 10, 2026. The agency announced the revised program July 31, followed by the August 3 Federal Register notice. These are approvals under that revised framework. [1] [3]

HRSA says the approach will improve transaction visibility, program integrity, and coordination with Medicare drug pricing. In its July 31 response, the American Hospital Association warned that the revised program would create substantial administrative costs and cash-flow pressure for hospitals. Those are competing assessments of a program whose operational results are still ahead. HRSA plans interim reporting and an evaluation by April 30, 2028. [3] [4] [1]

What to put on this week's agenda

Start with the work that will make January easier:

  1. Find your exposure. Match approved NDCs to recent utilization and purchases. Identify the affected sites, pharmacies, payers, and any applicable entity exceptions.
  2. Confirm the people and accounts. Name a Beacon administrator, a backup, and a finance contact. Verify organizational documentation, the bank letter, micro-deposits and any TPA authorization, including updates to an earlier Beacon registration.
  3. Walk through a sample transaction. Have pharmacy, the TPA, and finance trace the record from dispense through each required reporting system, the rebate submission and reconciliation. Record missing fields and who will correct them.
  4. Plan for the money in between. Estimate the additional purchase outlay and the effect of submission delays or returned claims. Set a review schedule for unpaid rebates.
  5. Prepare the year-end transition. HRSA provides a limited accommodation for up to two unreplenished accumulated packages during the 15-calendar-day period before implementation. Merck's plan applies that limit per NDC-11 and excludes dispenses already used to obtain 340B pricing. Review each applicable plan before clearing accumulations. GSK's notice describes a 15-day pre-start dispense window on page 2 and a 15-day post-start submission period on page 4; get written confirmation of the intended cutoffs before configuring that exception. [2] [7] [6]
  6. Check the billing handoff. Confirm how quarterly ceiling-price files will reach the people responsible for Medicaid billing and sliding-fee calculations. HRSA directs covered entities to work with their state Medicaid agencies on appropriate billing practices. [1]

A useful first meeting should end with named owners and a tested path for a claim. The goal is for the pharmacy team to know what gets purchased, the data team to know what gets submitted, and finance to know what should come back.

For help reviewing the affected products, testing your records, or preparing the supporting procedures, contact 340B Auditor.

Reference desk

Documents behind this update

Updated October 3, 2026 with the manufacturer communications distributed through Beacon. The original article was published October 1, 2026. The approval table links to HRSA-posted plans; the notice links below open the manufacturer documents listed by Beacon.

Program rules and context

  1. HRSA01
    340B Rebate Model Pilot Program

    The approval table, operating requirements, and FAQs. The manufacturer links above come from this page.

    Program page
  2. Federal Register02
    Notice Regarding 340B Rebate Model Pilot Program

    The federal framework for claims, payment timing, denials, and implementation.

    August 3, 2026 · 91 FR 48883 · PDF pp. 19–21
  3. HRSA03
    Announcement of the revised pilot

    HRSA's explanation of the revised program and its intended goals.

    July 31, 2026 · Agency announcement
  4. American Hospital Association04
    Hospital association response

    AHA's concerns about administrative costs and hospital cash flow.

    July 31, 2026 · Industry response

Manufacturer notices and implementation details

  1. AbbVie · Beacon05
    AbbVie rebate-model notice and FAQs

    Registration, selected-drug ESP routing, bank verification, payment timing and MFP coordination.

    October 2, 2026 · PDF pp. 1, 3–6
  2. GSK · Beacon06
    GSK participation notice

    Beacon and ESP routing, the ADAP exception, payment timing and transition wording.

    October 2, 2026 · PDF pp. 1–4
  3. Merck · Beacon07
    Merck manufacturer policy announcement

    Selected-drug claims move to Beacon; other applicable products remain in ESP. Includes registration and payment details.

    October 2, 2026 · PDF pp. 1–2
  4. Bristol Myers Squibb · Beacon08
    BMS rebate-model announcement

    Beacon setup, TPA authorization, contract-pharmacy requirements, payments and MFP coordination.

    October 2, 2026 · PDF pp. 1–5, 9
  5. Amgen · Beacon09
    Amgen 2027 rebate-model letter

    Beacon setup, renewed bank verification, TPA authorization and continuing claims-data collection requirements.

    October 1, 2026 · PDF pp. 1–2, 5–8
  6. Astellas · Beacon10
    Xtandi manufacturer policy announcement

    Registration timing recommendation, organizational and bank verification, and continuing contract-pharmacy policy.

    Listed by Beacon October 2, 2026 · PDF pp. 1–2
  7. AstraZeneca · Beacon11
    Farxiga rebate-model pilot policy

    Beacon rebate submissions alongside continued Farxiga claims reporting to 340B ESP.

    October 2, 2026 · PDF pp. 1–4
  8. Boehringer Ingelheim · Beacon12
    Boehringer 340B policy communication

    Pilot claims move to Beacon; ESP remains for other claims and pharmacy designations. Distinguishes the rebate and MFP platforms.

    October 2, 2026 · PDF pp. 1–3, 6–10
  9. Teva · Beacon13
    Teva public plan for Austedo and Austedo XR

    Separate Beacon registration, ongoing contract-pharmacy policy, payment timing and MFP adjustment.

    October 1, 2026 · PDF pp. 1–4, 6–9